In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Pacira BioSciences trades significantly below its PERT-weighted fair value of $99.17, indicating substantial upside potential amid high valuation confidence. However, profitability and efficiency scores are low, raising operational risk despite strong liquidity. Monte Carlo scenarios reveal high volatility but no downside risk below current price, suggesting asymmetrical return potential.